ECSP066649A - EFFECTIVE PREPARATION OF A PHARMACEUTICALLY ACTIVE BASIC SUBSTANCE - Google Patents

EFFECTIVE PREPARATION OF A PHARMACEUTICALLY ACTIVE BASIC SUBSTANCE

Info

Publication number
ECSP066649A
ECSP066649A EC2006006649A ECSP066649A ECSP066649A EC SP066649 A ECSP066649 A EC SP066649A EC 2006006649 A EC2006006649 A EC 2006006649A EC SP066649 A ECSP066649 A EC SP066649A EC SP066649 A ECSP066649 A EC SP066649A
Authority
EC
Ecuador
Prior art keywords
pharmaceutically active
basic substance
effective preparation
active basic
preparation
Prior art date
Application number
EC2006006649A
Other languages
Spanish (es)
Inventor
Wolfgang Wiehl
Irene Loose
Ralf Buellesbach
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of ECSP066649A publication Critical patent/ECSP066649A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

El objeto de la presente invención es una preparación efervescente que contiene una sal efervescente, al menos una sustancia básica farmacéuticamente activa y opcionalmente uno o más principios activos adicionales, caracterizada porque evita la alcalinización de la orina y con ello una acumulación aumentada de la sustancia básica farmacéuticamente activa, un fármaco que contiene esta preparación efervescente, procedimientos para su preparación y su uso.The object of the present invention is an effervescent preparation containing an effervescent salt, at least one pharmaceutically active basic substance and optionally one or more additional active ingredients, characterized in that it prevents the alkalization of the urine and thereby an increased accumulation of the basic substance pharmaceutically active, a drug that contains this effervescent preparation, procedures for its preparation and its use.

EC2006006649A 2003-12-19 2006-06-16 EFFECTIVE PREPARATION OF A PHARMACEUTICALLY ACTIVE BASIC SUBSTANCE ECSP066649A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10359790A DE10359790A1 (en) 2003-12-19 2003-12-19 Effervescent preparation of a basic pharmaceutically active substance

Publications (1)

Publication Number Publication Date
ECSP066649A true ECSP066649A (en) 2006-10-25

Family

ID=34683574

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006649A ECSP066649A (en) 2003-12-19 2006-06-16 EFFECTIVE PREPARATION OF A PHARMACEUTICALLY ACTIVE BASIC SUBSTANCE

Country Status (16)

Country Link
EP (1) EP1696874A1 (en)
JP (1) JP2007515418A (en)
KR (1) KR20060109492A (en)
CN (1) CN1893920A (en)
AR (1) AR046955A1 (en)
AU (1) AU2004308590A1 (en)
BR (1) BRPI0417796A (en)
CA (1) CA2550342A1 (en)
DE (1) DE10359790A1 (en)
EC (1) ECSP066649A (en)
IL (1) IL176356A0 (en)
MA (1) MA28276A1 (en)
MX (1) MXPA06006658A (en)
NO (1) NO20063327L (en)
WO (1) WO2005063199A1 (en)
ZA (1) ZA200604946B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
TR201107202T1 (en) * 2008-11-11 2012-02-21 Berko �La� Ve K�Mya Sanay� A.�. A pharmaceutical composition comprising ibuprofen, pseudoephedrine and chlorpheniramine.
KR101057640B1 (en) * 2009-05-27 2011-08-18 (주)다산메디켐 Multi-layer tablet comprising an effervescent layer
WO2013109224A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising diclofenac
CN104622831B (en) * 2013-11-06 2018-06-22 江苏豪森药业集团有限公司 A kind of oral tablet and preparation method thereof
CN107951034B (en) * 2017-12-01 2021-03-23 郑州拓洋生物工程有限公司 Vitamin effervescent preparation and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613497A (en) * 1984-02-29 1986-09-23 Health Products Development, Inc. Dry, water-foamable pharmaceutical compositions
CA2021548A1 (en) * 1989-09-01 1991-03-02 Ronald Nash Duvall Effervescent cold or sinus allergy medicine composition having reduced sodium content
CA2084028A1 (en) * 1991-11-27 1993-05-28 Harish B. Pandya Hot flu composition
AU7407194A (en) * 1993-08-03 1995-02-28 Warner-Lambert Company Pleasant tasting effervescent cold/allergy medications
JP2000063269A (en) * 1998-08-20 2000-02-29 Taiho Yakuhin Kogyo Kk Solid preparation

Also Published As

Publication number Publication date
CA2550342A1 (en) 2005-07-14
CN1893920A (en) 2007-01-10
WO2005063199A1 (en) 2005-07-14
BRPI0417796A (en) 2007-03-20
MA28276A1 (en) 2006-11-01
JP2007515418A (en) 2007-06-14
AU2004308590A1 (en) 2005-07-14
EP1696874A1 (en) 2006-09-06
DE10359790A1 (en) 2005-07-21
KR20060109492A (en) 2006-10-20
IL176356A0 (en) 2006-10-05
AR046955A1 (en) 2006-01-04
NO20063327L (en) 2006-07-18
MXPA06006658A (en) 2006-08-31
ZA200604946B (en) 2007-09-26

Similar Documents

Publication Publication Date Title
CU23367A3 (en) FORMULATION OF MOXIFLOXACINO WITH COMMON SALT
CL2007000601A1 (en) Compounds derived from pyrazolic heterobicycles, inhibitors of thyroxine kinase protein activity; pharmaceutical composition comprising said compounds; and use of the compounds in the treatment of a hyperproliferative disease.
UY27940A1 (en) FORMULATION OF HUMAN ANTIBODIES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH TNF-A
ECSP055525A (en) TYROSINE KINASE INHIBITORS
CL2007003520A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE PI3 QUINASA ACTIVITY; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE FOR CANCER PROFILACTIC OR THERAPEUTIC TREATMENT.
BRPI0410503B8 (en) topical composition and use of composition
ECSP088962A (en) NEW HERBICIDES
CL2007001427A1 (en) 5-AMINO-3- MALEATE SALT (2 ', 3'-DI-O-ACETYL-BETA-D-RIBOFURANOSIL) -3H-TIAZOLO [4,5-D] PIRIMIDIN-2-ONA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF A PO INFECTION
BRPI0718523B8 (en) DOSAGE FORM, AND METHOD FOR PREPARING THE DOSAGE FORM
CR11167A (en) USE OF HOMO AND COPOLIMEROS FOR THE STABILIZATION OF FORMULATIONS OF ACTIVE PRINCIPLES
NO20034323D0 (en) Medical aerosol formulations
ATE275393T1 (en) SOLID DISPERSIONS WITH NITRATACTIVE ACTIVE INGREDIENTS
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
ES2557988T3 (en) Method to treat prostate diseases based on the local supply of active ingredients
TW200640487A (en) Combination of XOLAIR with immunosuppressive agent
MX2007000117A (en) A COMBINATION COMPOSITION.
EA200800927A1 (en) COMPOSITION FOR AEROSOL INHALATION OF β-AGONISTS
CL2004001012A1 (en) COMPOUNDS DERIVED FROM MACROLIDS OF 14 OR 15 MEMBERS, REPLACED IN POSITION 4 "; PROCEDURE FOR PREPARATION; PHARMACEUTICAL COMPOSITION THAT INCLUDES IT; AND ITS USE FOR THE TREATMENT OR PROFILAXIS OF SYSTEMIC MICROBIAL OR TOPICAL INFECTIONS
ECSP066649A (en) EFFECTIVE PREPARATION OF A PHARMACEUTICALLY ACTIVE BASIC SUBSTANCE
AR046402A1 (en) COMBINATION OF ACTIVE PRINCIPLE THAT INCLUDES A 2,5-DIHYDROBENCENOSULPHONIC COMPOUND AND A POTASSIUM CHANNEL MODULATOR
CL2004001421A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM 1,4-DIPIPERIDIN-4-IL-PIPERAZINA; AND ITS USE FOR THE PREVENTION AND / OR TREATMENT OF PAIN.
AR043327A1 (en) USE OF QUINURENINE 3- HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES
AR058173A1 (en) USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES
AR036321A1 (en) METHOD AND PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF LATE APPEARANCE DYSCINESIA.
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent